Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;16(12):1691-701.
doi: 10.1080/15384047.2015.1095407.

Anaplastic lymphoma kinase: Role in cancer and therapy perspective

Zhihong Zhao  1 , Vivek Verma  2 , Mutian Zhang  2
Affiliations
Review

Anaplastic lymphoma kinase: Role in cancer and therapy perspective

Zhihong Zhao et al. Cancer Biol Ther. 2015.

Abstract

Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.

Keywords: anaplastic lymphoma kinase; cancer; inhibitor; resistance; therapy; tyrosine kinase.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The ALK receptor kinase: its domains, fusion break point, mutations, and resistance mutations. Reproduced with modification from Wellstein A, Toretsky JA. Hunting ALK to feed targeted cancer therapy. Nat Med. 2011; 17: 290–1. PMID: 21383740; doi: 10.1038/nm0311–290. © 2011 Nature America, Inc. By permission.
Figure 2.
Figure 2.
The ALK receptor kinase signaling pathways.
Figure 3.
Figure 3.
The ALK receptor kinase: fusion proteins. Reproduced with modification from Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic Lymphoma Kinase: role in specific tumors, and development of small molecule inhibitors for cancer therapy. Cancer Lett 2010; 299: 81–94. PMID: 20934803; doi: 10.1016/j.canlet.2010.09.001. © 2010 Elsevier Ireland Ltd. By permission.
See this image and copyright information in PMC

References

    1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117-34; PMID:20602996; http://dx.doi.org/ 10.1016/j.cell.2010.06.011 - DOI - PMC - PubMed
    1. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT, Saltman DL. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995; 267:316-7; PMID:7824924 - PubMed
    1. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9:1567-74; PMID:8183550 - PubMed
    1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al.. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-6; PMID:17625570 - PubMed
    1. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14:2175-88; PMID:9174053 - PubMed

MeSH terms

Substances